Source: NICE
Area: News
The National Institute for Health and Clinical Excellence (NICE) has published a costing statement to accompany its latest guidance on the use of dexamethasone intravitreal implants for the treatment of macular oedema caused by retinal vein occlusion (RVO).
According to this costing statement, implementation of this guidance in England (based on a population of 51.2 million) will result in net recurrent annual cost of £39,160,000 (equating to £76,000 per 100,000 local population).
Uncategorized